Method for selecting compounds for inhibition of neoplastic lesi

Details Method for selecting compounds for inhibition of neoplastic lesi Method for selecting compounds for inhibition of neoplastic lesi

1999-08-03

2000-10-10

Gitomer, Ralph

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving transferase

435 692, C12Q 148

Patent

active

061300535

ABSTRACT:
A method for selecting compounds for the treatment of neoplasia includes assessing whether the compounds cause an increase in PKG activity in the neoplasia of interest.

REFERENCES:
patent: 3031450 (1962-04-01), Fischer et al.
patent: 3161654 (1964-12-01), Shen
patent: 3322755 (1967-05-01), Roch et al.
patent: 3517005 (1970-06-01), Cronin et al.
patent: 3594480 (1971-07-01), Cronin et al.
patent: 3647858 (1972-03-01), Hinkley et al.
patent: 3654349 (1972-04-01), Shen et al.
patent: 3780040 (1973-12-01), Schnettler et al.
patent: 3812127 (1974-05-01), Cronin et al.
patent: 3819631 (1974-06-01), Broughton et al.
patent: 3865840 (1975-02-01), Carson
patent: 3920636 (1975-11-01), Takahasi et al.
patent: 4001237 (1977-01-01), Partyka et al.
patent: 4001238 (1977-01-01), Partyka et al.
patent: 4039544 (1977-08-01), Broughton et al.
patent: 4060615 (1977-11-01), Matier et al.
patent: 4076711 (1978-02-01), Ganguly et al.
patent: 4079057 (1978-03-01), Juby et al.
patent: 4098788 (1978-07-01), Crenshaw et al.
patent: 4101548 (1978-07-01), Crenshaw et al.
patent: 4102885 (1978-07-01), Crenshaw et al.
patent: 4138561 (1979-02-01), Crenshaw et al.
patent: 4146718 (1979-03-01), Jenks et al.
patent: 4161595 (1979-07-01), Kaplan et al.
patent: 4171363 (1979-10-01), Crenshaw et al.
patent: 4208521 (1980-06-01), Crenshaw et al.
patent: 4209623 (1980-06-01), Juby
patent: 4423075 (1983-12-01), Dvornik et al.
patent: 4457927 (1984-07-01), Biere et al.
patent: 4460590 (1984-07-01), Moller
patent: 4460591 (1984-07-01), DeGraw et al.
patent: 4837239 (1989-06-01), Benjamin et al.
patent: 4880810 (1989-11-01), Lowe, III et al.
patent: 4885301 (1989-12-01), Coates
patent: 4923874 (1990-05-01), McMahon et al.
patent: 4971972 (1990-11-01), Doll et al.
patent: 5073559 (1991-12-01), Coates
patent: 5091431 (1992-02-01), Tulshian et al.
patent: 5147875 (1992-09-01), Coates et al.
patent: 5175151 (1992-12-01), Afonso et al.
patent: 5223501 (1993-06-01), Chakravarty et al.
patent: 5239083 (1993-08-01), Kumazawa et al.
patent: 5250535 (1993-10-01), Verheyden et al.
patent: 5254571 (1993-10-01), Coates et al.
patent: 5358952 (1994-10-01), Moschel et al.
patent: 5376683 (1994-12-01), Klar et al.
patent: 5393755 (1995-02-01), Neustadt et al.
patent: 5401774 (1995-03-01), Pamukcu et al.
patent: 5439895 (1995-08-01), Lee et al.
patent: 5464861 (1995-11-01), Dobrusin et al.
patent: 5488055 (1996-01-01), Tulshian et al.
patent: 5614530 (1997-03-01), Kumar et al.
patent: 5614627 (1997-03-01), Takase et al.
patent: 5674876 (1997-10-01), Gilbert et al.
patent: 5696159 (1997-12-01), Gross et al.
patent: 5728563 (1998-03-01), Toshio et al.
patent: 5731167 (1998-03-01), Stracke et al.
patent: 5756818 (1998-05-01), Buchmann et al.
patent: 5798246 (1998-08-01), Au-Young et al.
patent: 5798373 (1998-08-01), Warrellow
patent: 5824305 (1998-10-01), Mynott
patent: 5846778 (1998-12-01), Hawkins et al.
patent: 5849770 (1998-12-01), Head et al.
patent: 5852035 (1998-12-01), Pamukcu et al.
patent: 5858694 (1999-01-01), Piazza et al.
patent: 5869519 (1999-09-01), Karanewsky et al.
patent: 5874440 (1999-02-01), Pamukcu et al.
patent: 5891896 (1999-04-01), Warrellow et al.
patent: 5922595 (1999-07-01), Fisher et al.
patent: 5932423 (1999-08-01), Au-Young et al.
patent: 5932465 (1999-08-01), Loughney
patent: 5942520 (1999-08-01), Pamukcu et al.
patent: 5948779 (1999-09-01), Sperl et al.
Waddell, W.R. et al., Am. J. Surgery, vol. 157, pp. 175-179 (1989).
Gilman, S.C. et al., Nonsteroidal Anti-inflammatory Drugs in Cancer Therapy, (circa 1985).
Duggan, D.E. et al., Clin. Pharm. & Therapeutics, vol. 21, No. 3, pp. 326-335 (1976).
Moorghen, M. et al., Journal of Pathology, vol. 156, pp. 341-347 (1988).
Silvola, J. et al., Effects of nonsteroidal anti-inflammatory drugs on rat gastric mucosal phosphodiesterase activity, Agents and Actions, vol. 12.4, pp. 516-520 (1982).
Curtis-Prior, P.B. et al., Cyclic Nucleotide Phosphodiesterase Activity of Human Normal and Carcinomatous Lung Tissue, The Lancet, pp. 1225-1225 Dec. 4, 1976.
Janik, P. et al., Inhibition of Growth of Primary and Metastatic Lewis Lung Carcinoma Cells by the Phosphodiesterase Inhibitor Isobutylmethylxanthine, Cancer Res. vol. 40, pp. 1950-1954,(Jun., 1980).
Drees, Markus et al., 3',5'-Cyclic Nucleotide Phosphodiesterase in Tumor Cells as Potential Target for Tumor Growth Inhibition, Cancer Research 53, pp. 3058-3061 (1993).
Semmler, J. et al., Xanthine derivatives: comparison between suppression of tumor necrosis factor-x production and inhibition of cAMP phosphodiesterase activity, Immunology 78, pp. 520-525 (1993).
Chang, W. et al., Sulindac Sulfone Modulates the Expression and Cellular Localization of b-Catenin in Human Colon Carcinoma Cells, Digestive Disease Week, Apr. 1, 1999.
Peifer, M., .beta.-Catenin as Oncogene: The Smoking Gun, Science, vol. 275, pp. 1752-1753, Mar. 21, 1997.
Korinek, V. et al., Constitutive Transcriptional Activation by a .beta.-Catenin-Tcf Complex in APC.sup.-/- Colon Carcinoma, Science, vol. 275, pp. 1784-1786, Mar. 21, 1997.
Morin, P. et al., Activation of .beta.-Catenin-Tcf Signaling in Colon Cancer by Mutations in .beta.-Catenin or APC, Science, vol. 275, pp. 1787-1789, Mar. 21, 1997.
Rubinfeld, B. et al., Stabilization of .beta.-Catenin by Genetic Defects in Melanoma Cell Lines, Science, vol. 275, pp. 1790-1792, Mar. 21, 1997.
Mahmoud, N. et al., Genotype-Phenotype Correlation in Murine Apc Mutation: Differences in Enterocyte Migration and Response to Sulindac, Cancer Research 59, pp. 353-359, Jan. 15, 1999.
Easwaran, V. et al., The Ubiquitin-Proteasome Pathway and Serine Kinase Activity Modulate Adenomatous Polyposis Coli Protein-mediated Regulation of .beta.-Catenin-Lymphocyte Enhancer-binding Factor Signaling, The Journal of Biological Chemistry, vol. 274, No. 23, pp. 16641-16645, Jun. 4, 1999.
Mahmoud, N. et al., Apc Gene Mutation is Associated with a Dominant-Negative Effect upon Intestinal Cell Migration, Cancer Research 57, pp. 5045-5050, Nov. 15, 1997.
Radomski, Marek W. et al., Human Colorectal adenocarcinoma cells: differential nitric oxide synthesis determines their ability of aggregate platelets (Abstract Only), Cancer Res. 51(22) pp. 6073-6078 (1991).
Jiang, X. et al., Inhibition of calmodulin-dependent phosphodiesterase induces apoptosis in human leukemic cells, Proc. Natl. Acad. Sci. USA, vol. 83, pp. 11236-11241, Oct. 1996.
Earnest, D. et al., Piroxicam and Other Cyclooxygenase Inhibitors: Potential for Cancer Chemoprevention, Journal of Cellular Biochemistry, Supplement 161:156-166 (1992).
Blaya, C. et al., Effect of the protein kinase inhibitors, 1-(5-isoquinolinylsulfonyl)-2-methylpiperazine H-7 and N-(2-[methylamino]ethyl)-5-isoquinoline-sulfonamide H-8 on Lewis lung carcinoma tumor progression, European Journal of Pharmacology, 354, pp. 99-104 (1998).
Ahlstrom, M.; Lamberg-Allardt, C., Regulation of adenosine 3',5'-cyclic monophosphate (cAMP) accumulation in UMR-106 osteoblastlike cells: role of cAMP-phosphodiesterase and cAMP efflux, Biochem. Pharmacol. (1999), 58(8), 1335-1340.
Ahn, H.S. et al., Effects of Selective Inhibitors on Cyclic Nucleotide Phosphodiesterases of Rabbit Aorta, Biochemical Pharmacology, vol. 38, No. 19, pp. 3331-3339 (1989).
Ahn, Ho-Sam et al., Potent Tetracyclic Guanine Inhibitors of PDE1 and PDE5 Cyclic Guanosine Monophosphate Phosphodiesterases with Oral Antihypertensive Activity; J. Med. Chem. 1997, 40, pp. 2196-2210.
Altiok N. et al., Bradykinin inhibition of cyclic AMP accumulation in D384 astrocytoma cells. Evidence against a role of cyclic GMP, Neurochem Int. Sep. 1992; 21(2):209-13.
Anderson, Thomas L. G. et al., Interactions between isoprenaline, sodium nitroprusside, and isozyme-selective phosphodiesterase inhibitors on ADP-induced aggretation and cyclic Nucleotide levels in human platelets (Abstract Only), J. Cardiovasc. Pharmacol. 18(2) pp. 237-242 (1991).
Antonenko S.G. et al., [The role of the components of the cyclic nucleotide system in N-nitrosodiethylamine-induced hepatic carcinogenesis in rats] (Article in Russian), Eksp. Onkol. 1990;12(5):18-21.
Badreih, Y., et al., Chem. Ber., v

Affiliated with

Also associated with

Rating

Method for selecting compounds for inhibition of neoplastic lesi does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method for selecting compounds for inhibition of neoplastic lesi, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for selecting compounds for inhibition of neoplastic lesi will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2255258